Search Clinical Trials in the EU

Duration

Visits

Phase

Oral

Benefits

Drugs

Locations

Clinical Specialty

501-520 of 1,694 trials

Prostate Cancer: 12-Month Treatment Study

We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.

Low-Volume Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesOncologyUrology

Rectal Cancer Treatment: Comparing Therapies for Older Patients

We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.

Rectal Cancer6-12 monthsConfirmation phase (III)No Placebo Standard Medicines Cost ReimbursementOncology

Crohn's Disease: TAK-279 Oral Medication

We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Aggressive Large B-Cell Lymphoma: Golcadomide After CAR T-Cell Therapy

We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.

Aggressive Large B-Cell Lymphoma>2 yearsEfficacy phase (II)No Placebo Investigational MedicinesHematologyOncology

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesHematologyOncology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Partially RemoteOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyOncology

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Partially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesGastroenterologyOncology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncology

Ulcerative Colitis: TAK-279 Oral Medication

We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Pulmonary Hypertension: Long-term Safety Study

We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemotePulmonology

Adrenomyeloneuropathy: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.

Adrenomyeloneuropathy>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access Investigational MedicinesNeurology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesInternal MedicineOtolaryngologyPediatrics

LSTA1 for Newly Diagnosed Glioblastoma Multiforme

We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.

Glioblastoma Multiforme>2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost ReimbursementOncology

Prostate Cancer: Intermittent vs. Continuous Hormone Therapy

We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.

Hormone-sensitive Metastatic Prostate Cancer>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard MedicinesOncologyUrology

Mycobacterium Xenopi Infection: ARIKAYCE Inhalation Treatment

We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.

Mycobacterium xenopi Pulmonary Infection>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard MedicinesInfectious DiseasesPulmonology

Metastatic Prostate Cancer: ProBio Study

We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.

Metastatic Prostate CancerConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncologyUrology

Late Renal Graft Failure: Immunosuppression Study

We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.

Kidney Transplant>2 yearsMonitoring phase (IV)No Placebo Investigational MedicinesInternal MedicineNephrology

Search Clinical Trials in the European Union